Please login to the form below

Not currently logged in

LabCorp to acquire Covance for $5.6bn

Combines diagnostics expertise with contract research
Covance boxes

Diagnostics firm Laboratory Corporation of America Holdings (LabCorp) has added drug development to its business with the acquisition of contract research organisation Covance.

The deal, valued at $5.6bn, creates one of the world's leading healthcare diagnostic companies, combining LabCorp's expertise in medical testing and the full-service drug development of Covance, which includes market access and nutritional businesses.

The combined company will leverage technologies that improve patient recruitment for clinical trials, enhance efficiency in the conduct of clinical trials and deliver data faster to drug sponsors, physicians and patients.

LabCorp chairman and CEO David P King and LabCorp chief financial officer Glenn Eisenberg will serve in the same positions for the combined company. Covance chairman and CEO Joe Herring will lead LabCorp's Covance division and report directly to King.

King commented: “By joining our highly compatible and complementary capabilities, the combined company will be an industry leader in both the laboratory and CRO spaces, characterised by global scale, enhanced offerings, new efficiencies, broader and deeper customer relationships, and a differentiated business model.”

Herring added: “We are thrilled to join forces with another industry leader through a transaction that delivers to our shareholders substantial immediate cash value along with a meaningful stake in a combined company with exciting growth opportunities.”

The combined company will remain at LabCorp's headquarters in Burlington, North Carolina, while the Covance division headquarters will still be based in Princeton, New Jersey.

The transaction is expected to close in the first quarter of 2015.

Article by
Kirstie Pickering

5th November 2014

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...